Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 193
Tipo Título / Nombre Autor(es) Año
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry Sargas C, Ayala R, Larráyoz MJ, Chillón MC..., Bergua JM 2023
Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols Barba P, Morgades M, Montesinos P, Gonzalez-Campos J, Torrent A, Gil C..., Bergua J 2023
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia Simoes C, Chillon MC, Martínez-Cuadrón D, Calasanz MJ..., Bergua Burgues JM 2022
Pharmacokinetics and Pharmacodynamics in First-MIND: A Phase Ib, Open-Label, Randomized Study of Tafasitamab ± Lenalidomide + R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Belada D, Kopeckova K..., Bergua J 2022
Midostaurin Maintenance versus Allo SCT versus W&W in FLT3-Mutated AML: A “Real-Life” Multicenter Study Fuente A de la, Díaz Beya M..., Bergua J 2022
Impact of center characteristics and macroeconimic factors on the outcome of adult patients with acute lymphoblastic leukemia treated with peiatric-inspired protocols Barba P, Morgades M, Montesinos P, González Campos J..., Bergua Burgues J 2022
Midostaurin plus intensive chemotherapy in FLT3 mutated AML De la Fuente A, Diaz Beya M, Beneit P..., Bergua Burgues J 2022
Real life experience using front-line CPX-351 for therapy-related and AML-MRC: results from the spanish Pethema registry Bernal T, Rad G, Laiglesia A de, Benavente C..., Bergua Burgues J 2022
Pharmacokinetics and pharmacodynamics in first-mind: a phase IB, open-label, randomized study of tafasitamab+ + lenalidomide + R-Chop in patients with newly diagnosed diffuse large B-cell lymphoma Belada D, Kopeckova K, Bergua Burgues J, Stevens D..., Dreyling M 2022
Preliminary results of VEN-A-QUI Study: a phase 1-2 trial to assess the safety and efficacy of the combination of azacitidine or low- dose cytarabine with venetoclax and quizartinib in newly diagnosed Bergua Burgues JM, Rodríguez Veiga R, Cano I..., Casas Avilés I 2022